A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
Study Details
Study Description
Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of AZD6912 administered subcutaneously (SC) in healthy participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
In this First-In-Human (FiH) study, eligible participants will be randomly assigned to 6 cohorts in a 3:1 ratio to receive either a single dose of AZD6912 SC or placebo. The first 2 participants in each cohort will be dosed as a sentinel pair, with one receiving AZD6912 SC and the other receiving placebo.
The study will comprise of, a screening period of 70 days, a treatment period where participants will stay at the Clinical Unit from the day before study intervention administration until at least 240 hours and will be discharged on Day 11. Outpatient visits would start weekly from Day 15, then bi-weekly from Day 43, 4-weekly from Day 99, and 6-weekly from Day 155, with additional follow-up visits as needed.
The study will last approximately 22 months, with each participant participating for about 38 weeks.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: AZD6912 Dose 1 Participants will receive AZD6912 Dose 1. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 Dose 2 Participants will receive AZD6912 Dose 2. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 Dose 3 Participants will receive AZD6912 Dose 3. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 Dose 4 Participants will receive AZD6912 Dose 4. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 Dose 5 Participants will receive AZD6912 Dose 5. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 Dose 6 Participants will receive AZD6912 Dose 6. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Placebo Comparator: Placebo Participants will receive Placebo. |
Drug: Placebo
Placebo will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 additional cohort 1 -including Japanese Participants Participants will receive AZD6912. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
| Experimental: AZD6912 additional cohort 2 -including Japanese Participants Participants will receive AZD6912. |
Drug: AZD6912
AZD6912 will be administered as a single sub-cutaneous dose.
|
Outcome Measures
Primary Outcome Measures
- Number of participants with adverse events (AEs) [From screening (Day -70) to last follow up visit (Day 197- approximately 38 weeks)]
To assess the safety and tolerability of AZD6912 in healthy participants.
Secondary Outcome Measures
- Maximum observed plasma (peak) drug concentration (Cmax) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise the Cmax of single ascending doses of AZD6912 in healthy participants.
- Area under plasma concentration-time curve from zero to infinity (AUCinf) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise AUCinf of single ascending doses of AZD6912 in healthy participants.
- Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise the AUClast of single ascending doses of AZD6912 in healthy participants.
- Time to reach peak or maximum observed concentration or response following drug administration (tmax) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise tmax of single ascending doses of AZD6912 in healthy participants.
- Time of last measurable concentration (tlast) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise tlast of single ascending doses of AZD6912 in healthy participants.
- Terminal elimination half-life (t½λz) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise t½λz of single ascending doses of AZD6912 in healthy participants.
- Dose normalised AUClast (AUClast/D) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise AUClast/D of single ascending doses of AZD6912 in healthy participants.
- Dose normalised AUCinf (AUCinf/D) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise AUCinf/D of single ascending doses of AZD6912 in healthy participants.
- Dose normalised Cmax (Cmax/D) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise Cmax/D of single ascending doses of AZD6912 in healthy participants.
- Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise CL/F of single ascending doses of AZD6912 in healthy participants.
- Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F) of AZD6912 [From randomization to Day 197 (up to 28 weeks)]
To characterise Vz/F of single ascending doses of AZD6912 in healthy participants.
- Percent change from baseline in plasma concentrations of Complement factor B (CFB) protein [From randomization to Day 197 (up to 28 weeks)]
To assess the PD effects of single ascending doses of AZD6912 in healthy participants.
- Percent change from baseline in serum of Complement functional activity (CAP) [From randomization to Day 197 (up to 28 weeks)]
To assess the PD effects of single ascending doses of AZD6912 in healthy participants.
- Number of participants with positive Anti-Drug Anitbody (ADA) [From randomization to Day 197 (up to 28 weeks)]
To evaluate the immunogenicity of single ascending doses of AZD6912 in healthy participants.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Females must have a negative pregnancy test.
-
Contraceptive use by males and females should be consistent with local regulations.
-
Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
-
For optional Japanese participants only:
-
Participants must be of Japanese descent defined as: first generation (born to 2 Japanese parents and 4 Japanese grandparents).
-
Born in Japan, and not have lived outside Japan for more than 5 years.
-
Lifestyle, including diet, must not have significantly changed since leaving Japan.
Exclusion Criteria:
-
History of any clinically important disease or disorder.
-
Current or recurrent disease of clinical significance that could affect clinical assessments or clinical laboratory evaluations.
-
Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
-
History of congenital or acquired immunodeficiency or complement deficiency or an underlying condition that predisposes to infection.
-
History of any Neisseria infection, unexplained, recurrent infections, or infection requiring treatment with systemic antibiotics.
-
Evidence of hepatitis B infection (positive for HBsAg or positive for anti-HBcAb) or hepatitis C viral infection (HCV Abs or hepatitis C RNA positive) or HIV infection (positive for HIV type 1 or type 2 Abs).
-
Participants testing positive for COVID-19 prior to dosing.
-
Any cardiac abnormalities.
-
A CAP activity < 60% at screening.
-
Known or suspected history of drug abuse, history of alcohol abuse or smoking.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AstraZeneca
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D7130C00001